Merck & Co. completed a $10 billion acquisition of Verona Pharma to expand its cardio-pulmonary disease portfolio, acquiring Verona’s COPD drug and associated assets. The deal focuses on leveraging Verona’s fast-growing therapeutics amid expiring primary patents, relying on secondary patents’ strength for protection. This strategic buy aligns with Merck’s expansion into lung disease and respiratory treatments, reflecting growing market focus on chronic pulmonary conditions.